Table 3. Clinical data, and diffusion and perfusion parameters in contrast-enhancing and non-enhancing regions according to survivala.
| Characteristic | Survival < 6 months (n = 8) | Survival > 6 months (n = 7) | p-value |
|---|---|---|---|
| Male/Female | 37.5% /62.5% | 57.1% /42.9% | 0.447 |
| Age | 68.5 (63.75–72.5) | 69 (59.5–75) | 1.00 |
| Motor deficit (%) | 50 | 42.9 | 0.782 |
| Language deficit (%) | 50 | 14.3 | 0.143 |
| Karnofsky Performance Score | 90 (80–100) | 90 (85–95) | 0.903 |
| CER (mL) | 16.05 (12.28–19.67) | 13.82 (8.48–23.78) | 0.779 |
| Necrosis (mL) | 5.47 (2.95–10.18) | 4.11 (2.15–7.05) | 0.397 |
| NCER (mL) | 49.66 (34.43–70.23) | 33.99 (26.01–58.11) | 0.281 |
| fCER (%) | 11.43 (10.64–14.53) | 9.13 (7.63–10.41) | 0.009 |
| DCER (x10-3mm2/s) | 0.997 (0.904–1.056) | 1.115 (1.040–1.260) | 0.121 |
| D*CER (x10-3mm2/s) | 26.448 (24.774–30.702) | 20.507 (18.254–23.601) | 0.021 |
| ADCCER(x10-3mm2/s) | 100.39 (88.9–113.83) | 123.51 (106.48–131.59) | 0.072 |
| rCBFCER (ml/100g/min) | 67 (47.12–78.48) | 46.15 (28.24–49.87) | 0.04 |
| rCBVCER (ml/100g) | 5.57 (4.67–6.51) | 3.87 (2.95–4.55) | 0.04 |
| max rCBFCER (ml/100g/min) | 165.9 (156.2–173.4) | 140.5 (133.2–147.7) | 0.07 |
| max rCBVCER (ml/100g) | 14.1 (11.0–16.8) | 10.6 (9.9–11.5) | 0.04 |
| fNCER (%) | 2.27 (1.18–3.11) | 2 (1.94–3.15) | 0.602 |
| DNCER (x10-3mm2/s) | 1.381 (1.267–1.662) | 1.486 (1.305–1.787) | 0.779 |
| D*NCER (x10-3mm2/s) | 6.352 (3.752–7.204) | 3.764 (2.523–4.264) | 0.094 |
| rCBFNCER (ml/100g/min) | 23.69 (13.37–33.67) | 22.92 (17.39–23.68) | 0.779 |
| rCBVNCER (ml/100g) | 1.06 (0.85–1.43) | 1.75 (1.31–1.86) | 0.336 |
| Treatment | 0.067 | ||
| Standard (n) | 1 | 4 | |
| Non-standard (n) | 7 | 3 | |
| Survival (months) | 4 (2–5.25) | 8.5 (7–10) | 0.001 |
a Significant p-values are highlighted.